Publications by authors named "Dusit Jit-Ueakul"
Endothelial activation and stress index as a prognostic factor of diffuse large B-cell lymphoma: the report from the nationwide multi-center Thai Lymphoma Study Group.
Ronakrit Thanhakun Kitsada Wudhikarn Udomsak Bunworasate Thanawat Rattanathammethee Lalita Norasetthada Dusit Jit-Ueakul
Ann Hematol
December 2023
Several prognostic models have been introduced to predict outcomes of patients with diffuse large B-cell lymphoma (DLBCL). Endothelial activation and stress index (EASIX) is a surrogate of endothelial dysfunction which has been shown to predict outcomes of patients with various hematologic malignancies. However, the prognostic implication of EASIX for DLBCL is limited and warrants exploration.
View Article and Find Full Text PDFOutcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
Thanawat Rattanathammethee Lalita Norasetthada Udomsak Bunworasate Kitsada Wudhikarn Jakrawadee Julamanee Dusit Jit-Ueakul
Ann Hematol
July 2023
Article Synopsis
- Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is tough to treat, and there's a need for better therapies; polatuzumab vedotin (Pola), combined with bendamustine-rituximab (BR), has recently been approved for patients.
- A study in Thailand included 35 patients treated with Pola, showing a 62.8% overall response rate (ORR) and survival outcomes better than 180 patients receiving non-Pola therapies.
- Despite some serious adverse events reported, they were manageable, indicating that Pola-based treatment could be a promising option for R/R DLBCL patients with limited alternatives.